Harshamitra Oncology Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 3.68 Cr
as on 26-07-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.29 Cr
as on 26-07-2024
- Revenue 18.10%
(FY 2023)
- Profit -27.74%
(FY 2023)
- Ebitda -10.63%
(FY 2023)
- Net Worth -34.52%
(FY 2023)
- Total Assets -15.70%
(FY 2023)
About Harshamitra Oncology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.68 Cr.
The company currently has active open charges totaling ₹13.29 Cr.
The Key Managerial Personnel (KMP) at Harshamitra Oncology Private Limited India is Govindaraj Ganesan as CEO. Govindaraj Ganesan and Sasipriya Ponniah serve as directors at the Company.
- CIN/LLPIN
U74999TN2014PTC095975
- Company No.
095975
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruchirappalli, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Harshamitra Oncology?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindaraj Ganesan  | Managing Director | 30-May-2014 | Current |
| Sasipriya Ponniah | Managing Director | 30-May-2014 | Current |
Board Members(0)
| Name | Designation | Appointment Date | Status |
|---|
Financial Performance of Harshamitra Oncology.
Harshamitra Oncology Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.1% increase. The company also saw a substantial fall in profitability, with a 27.74% decrease in profit. The company's net worth observed a substantial decline by a decrease of 34.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harshamitra Oncology?
In 2023, Harshamitra Oncology had a promoter holding of 99.73% and a public holding of 0.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Harshamitra Super Speciality Cancer Centre & Research Institute Private LimitedActive 9 years 7 monthsGovindaraj Ganesan and Sasipriya Ponniah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 04 Sep 2023 | ₹1.06 Cr | Open |
Indian Bank Creation Date: 23 Dec 2021 | ₹6.53 M | Open |
Indian Bank Creation Date: 08 Dec 2017 | ₹6.58 Cr | Open |
How Many Employees Work at Harshamitra Oncology?
Unlock and access historical data on people associated with Harshamitra Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harshamitra Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harshamitra Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
